The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer

Journal of Rheumatology

Volumn 42, Issue 1, 2015, Pages 55-59

  Chen, Jason Y ^a   Ballou, Stanley P ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Autoimmune diseases; Estrogen receptor positive; Rheumatoid arthritis; Selective estrogen receptor modulators; Systemic lupus erythematosus

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; EXEMESTANE; FORMESTANE; LETROZOLE; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ADULT; ARTICLE; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; ARTHRITIS, RHEUMATOID; BREAST NEOPLASMS; CHEMICALLY INDUCED; DOSE RESPONSE; FACTUAL DATABASE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RISK; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BREAST NEOPLASMS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RISK; YOUNG ADULT;

EID: 84920369017     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140367     Document Type: Article

References (16)

1. O'Neill S, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2010;24:841-55.
2. Carmona L, Cross M, Williams B, Lassere M, March L. Rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010; 24:733-45.
3. Tedeschi SK, Bermas B, Costenbader KH. Sexual disparities in the incidence and course of SLE and RA. Clin Immunol 2013; 149:211-8.
4. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008;173:600-9.
5. Wilson KB, Evans M, Abdou NI. Presence of a variant form of the estrogen receptor in peripheral blood mononuclear cells from normal individuals and lupus patients. J Reprod Immunol 1996;31:199-208.
6. Ishizuka M, Hatori M, Suzuki T, Miki Y, Darnel AD, Tazawa C, et al. Sex steroid receptors in rheumatoid arthritis. Clin Sci 2004;106:293-300.
7. Wang J, Nuite M, McAlindon TE. Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus 2010;19:734-40.
8. Capellino S, Riepl B, Rauch L, Angele P, Cutolo M, Straub RH. Quantitative determination of steroid hormone receptor positive cells in the synovium of patients with rheumatoid arthritis and osteoarthritis: is there a link to inflammation? Ann Rheum Dis 2007;66:53-8.
9. Sthoeger ZM, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 2003;62:341-6.
10. Roman-Blas JA, Castañeda S, Cutolo M, Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor β ?agonist, ERB-041, in patients with rheumatoid arthritis: A 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res 2010;62:1588-93.
11. Mok CC, Ying SKY, Ma KM, Wong CK. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. Lupus 2013;22:1470-8.
12. Kaelber DC, Foster W, Gilder J, Love TE, Jain AK. Patient characteristics associated with venous thromboembolic events: A cohort study using pooled electronic health record data. J Am Med Inform Assoc 2012;19:965-72.
13. International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. [Internet. Accessed September 9, 2014]. Available from: http://globocan.iarc.fr/Default.aspx.
14. Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L, et al. Defining the aromatase inhibitor musculoskeletal syndrome: A prospective study. Arthritis Care Res 2012;64:1910-8.
15. Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol 2014;143C:207-22.
16. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006;58:773-81.